SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-053330
Filing Date
2020-11-12
Accepted
2020-11-12 08:51:04
Documents
61
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-10q_20200930.htm 10-Q 2527315
2 EX-10.1 trvi-ex101_80.htm EX-10.1 333381
3 EX-31.1 trvi-ex311_9.htm EX-31.1 13956
4 EX-31.2 trvi-ex312_6.htm EX-31.2 13921
5 EX-32.1 trvi-ex321_7.htm EX-32.1 8650
6 EX-32.2 trvi-ex322_8.htm EX-32.2 8757
  Complete submission text file 0001564590-20-053330.txt   7177294

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT trvi-20200930.xml EX-101.INS 1170675
8 XBRL TAXONOMY EXTENSION SCHEMA trvi-20200930.xsd EX-101.SCH 50532
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE trvi-20200930_cal.xml EX-101.CAL 46554
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE trvi-20200930_def.xml EX-101.DEF 141161
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20200930_lab.xml EX-101.LAB 382003
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20200930_pre.xml EX-101.PRE 288385
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 201303760
SIC: 2834 Pharmaceutical Preparations